Biomark Diagnostics (Biomark Diagnostics) EBIT

: $-1.07 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Biomark Diagnostics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.07 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biomark Diagnostics's annualized ROC % for the quarter that ended in Dec. 2023 was -134.27%. Biomark Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -229.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biomark Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -5.64%.

Biomark Diagnostics EBIT Historical Data

The historical data trend for Biomark Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

-0.41

-0.87

-1.11

-1.27

Biomark Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT																-0.27	-0.35	-0.30	-0.14	-0.29

Competitive Comparison

For the Diagnostics & Research subindustry, Biomark Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomark Diagnostics EV-to-EBIT Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's EV-to-EBIT falls into.

Biomark Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.07 Mil.

Biomark Diagnostics (OTCPK:BMKDF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biomark Diagnostics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-1.152 * ( 1 - 0% )	/	( (0.586	+	1.13)	/ 2 )
=	-1.152	/	0.858
=	-134.27 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.467	-	0.93	-	( 0.124	-	max(0, 1.211	-	0.162	+	0.124	))
=	0.586

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.006	-	0.609	-	( 0.233	-	max(0, 1.016	-	0.283	+	0.233	))
=	1.13

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Biomark Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.152	/	( ( (0.293 + max(-0.9, 0))	+	(0.709 + max(-0.566, 0)) )	/	2 )
=	-1.152	/	( ( 0.293	+	0.709 )	/	2 )
=	-1.152	/	0.501
=	-229.94 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.022	+	0	+	0.016)	-	(0.93	+	0.007	+	0.0010000000000001)
=	-0.9

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.035	+	0	+	0.015)	-	(0.609	+	0.006	+	0.0010000000000001)
=	-0.566

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biomark Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-1.072	/	19.016
	=	-5.64 %

Biomark Diagnostics EBIT Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics (Biomark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

BUX:Canada

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines